Optiscan Imaging Ltd (Optiscan) is a medical technology company that specializes in digital pathology and precision surgery. The company focuses on developing real-time, non-invasive microscopic imaging solutions that enhance clinical decision-making and improve patient outcomes. Optiscan serves the healthcare and life sciences industries by providing advanced imaging technologies that facilitate earlier disease detection and management. The company through its patented technology develops high power miniature confocal microscopes that can be used inside the body of humans and animals.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D efforts focus on the development of new and innovative products in microscopic imaging. The company is exploring various applications for its transformative technology, including telepathology, artificial intelligence-enhanced image analysis, and integration with robotic systems for precision surgery. Optiscan is also advancing innovative gastrointestinal applications and is exploring opportunities in oral, cervical, surgical, and veterinary medicine. The company is committed to developing biopsy channel-compatible devices and advancing image-guided molecular surgery through ongoing in-house research and collaboration with academic institutions and industry partners. In FY2025, the company spent AUD5.1 million on its R&D activities, which grew 30.8% YoY.